Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). Methods Systematic reviews were conducted...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Breast cancer research and treatment Ročník 180; číslo 3; s. 597 - 609
Hlavní autoři:	Paracha, Noman, Reyes, Adriana, Diéras, Véronique, Krop, Ian, Pivot, Xavier, Urruticoechea, Ander
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	New York Springer US 01.04.2020 Springer Springer Nature B.V
Témata:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Bridged-Ring Compounds - administration & dosage Cancer research Care and treatment Clinical trials ErbB-2 protein Female Humans Immunotherapy Inhibitor drugs Medicine Medicine & Public Health Meta-analysis Metastases Metastasis Molecular Targeted Therapy Monoclonal antibodies Oncology Pertuzumab Receptor, ErbB-2 - antagonists & inhibitors Review Survival Targeted cancer therapy Taxoids - administration & dosage Thrombocytopenia Trastuzumab Trastuzumab - administration & dosage Treatment Outcome Trastuzumab emtansine Lapatinib Pertuzumab Capecitabine Neratinib Locally advanced
ISSN:	0167-6806, 1573-7217, 1573-7217
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!